Johnson & Johnson Showcases Achievements in Supporting 'Common Prosperity' at the Fifth China International Import Expo

Promote the Inclusiveness of Medical Resources for the People and Support the Great Vision of Common Prosperity

ShanghaiNovember 6, 2022PR Newswire -- Today, Johnson & Johnson, a global leader in healthcare, showcased several innovative initiatives and fruitful outcomes aimed at supporting the goal of "common prosperity" at the Fifth China International Import Expo. On its 1,000-square-meter booth, Johnson & Johnson displayed nearly 200 innovative products from its medical technology, pharmaceuticals, and consumer health businesses, as well as achievements in digitally-enabled healthcare innovation. Additionally, a special section titled "Co-creating a Healthy Society" was set up. During the company's press conference on the same day, Johnson & Johnson introduced its efforts and progress in supporting the government to promote accessible quality healthcare resources for the public, enhance the health and well-being of Chinese citizens, and advance the realization of the grand vision of "common prosperity."

"Creating a Healthy Society Together" Special Zone at the Johnson & Johnson Booth of the 5th CIIE

Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China, stated: "Healthcare is an essential component of common prosperity. As a leader in the healthcare industry, Johnson & Johnson remains steadfast in supporting 'common prosperity.' As a 'long-time friend' participating in the China International Import Expo (CIIE) for the fifth consecutive time, Johnson & Johnson is delighted to share its 'China story' in supporting 'common prosperity' on the CIIE platform. At the same time, we are pleased to see that numerous implemented projects have effectively advanced the availability of more advanced medical resources and services to grassroots levels, benefiting the health and well-being of a broader population across China."

In December 2021, Johnson & Johnson announced six key initiatives under three major strategies to help build a "healthy defense line" for "common prosperity." These strategies are: "Empowering vitality and driving innovation to support the construction of a high-quality healthcare system; Science-based, supporting the construction of a public health system; Giving back to society and practicing corporate social responsibility." Johnson & Johnson became the first world-leading multinational enterprise to announce its support for "common prosperity." Multiple practical projects by Johnson & Johnson in support of "common prosperity" have been implemented, achieving remarkable results.

Innovation-Driven, Supporting the Construction of a High-Quality Healthcare System

Johnson & Johnson accelerates the introduction of globally leading innovative medical products and solutions, working together with the government and industry to ensure more patients can access and afford innovative treatment options.ToCurrently, Johnson & Johnson has provided free training to medical personnel totaling 12 million person-times. Of its 32 pharmaceutical products, 26 have been included in the National Medical Insurance Catalog, and its innovative medical products cover more than 10,000 hospitals at all levels across China. Johnson & Johnson supports the National Health Commission in providing professional skills training in multiple fields for young and middle-aged medical workers as well as frontline medical staff, including basic surgical skills training, intracerebral hemorrhage, stroke, and interventional diagnosis and treatment capabilities for cardiovascular diseases, strongly promoting the availability of high-quality medical resources at grassroots levels. JLABS @ Shanghai, Johnson & Johnson’s largest global and first innovation incubator in the Asia-Pacific region, has welcomed 72 start-up companies, with the total value of financing and strategic relationships obtained by resident enterprises exceeding 3.5 billion US dollars.

Johnson & Johnson continues to increase its investment in local R&D and innovation in China, collaborating with the government, industry, academia, research institutions, and local innovation partners to build an open healthcare innovation ecosystem. Among these efforts, Johnson & Johnson has established a comprehensive partnership with Hangzhou DuoXi Biotechnology Co., Ltd., a local biopharmaceutical company, leveraging its unique innovative platform to jointly develop novel ADC drugs. Meanwhile, Johnson & Johnson has also partnered with WuXi AppTec's subsidiary, WuXi XenoBiotics Laboratories, utilizing its advanced TESSA technology.^™Patented technology, jointly advancing innovative gene therapies.

Science-Based, Supporting the Construction of Public Health Systems

Johnson & Johnson Leverages Core Competencies in Science and Innovation to Address Public Health Challenges and Serve the Health of All CitizensJohnson & Johnson leverages its core competencies in science and innovation to help society collectively address public health challenges and serve the health needs of all citizens. For instance, the company signed a strategic cooperation memorandum with the National Center for Infectious Diseases to jointly build an anti-infective ecosystem. By actively exploring screening and referral models for patients in districts and counties, it promotes the detection and timely referral of multidrug-resistant tuberculosis patients. To date, eight demonstration centers have been established, covering more than 60 districts and counties. Concurrently, grassroots doctor training and patient education programs are being conducted to reduce the risk of societal transmission. Additionally, Johnson & Johnson supports the government in implementing and advancing an innovative integrated hospital-community management model for schizophrenia patients to improve treatment methods and help patients and their families regain social functionality. Notably, the hospital-community integration project targeting community-residing schizophrenia patients has been actively progressing across China. As of September 2022, nine provincial projects and 37 municipal projects had been launched, benefiting more than 20,000 schizophrenia patients who received free long-acting injectable treatments.

Give Back to Society, Practice Corporate Social Responsibility

Johnson & Johnson Invests More Resources in Empowering Grassroots Healthcare Workers, Crisis Response, and Charitable DonationsOver the past six years, Johnson & Johnson has donated more than 1.2 billion RMB to support social welfare, disaster relief, and patient assistance programs. By establishing a Global Community Impact Special Fund, Johnson & Johnson is expected to invest over 150 million RMB to support the government in providing free training for grassroots healthcare workers. The first phase of the project will reach more than 200,000 grassroots health workers, benefiting 20 million patients. As a key initiative in fulfilling corporate social responsibility, Johnson & Johnson supports the public welfare project "Capacity Building for the Prevention and Treatment of Common Elderly Diseases in Communities." Focused on chronic conditions such as atrial fibrillation and cataracts, the project aims to enhance the medical service capabilities of community health workers and promote a scientific approach to preventing common diseases among the elderly. Additionally, Johnson & Johnson continues to improve rural healthcare infrastructure by supporting the construction of Boai Health Stations under the China Red Cross Foundation. Through educational campaigns and free clinics, it helps elevate grassroots medical standards and the health-related quality of life for local residents, promoting equitable access to quality healthcare resources. In September this year, Johnson & Johnson China announced a donation of 1 million RMB to the China Red Cross Foundation to support the renovation and rebuilding of multiple Boai Clinics and Health Centers in areas affected by the earthquake in Luding County, Garze Tibetan Autonomous Prefecture, Sichuan Province.

At the same time, Johnson & Johnson has built a comprehensive internal platform to provide employees with resources for participating in various social public welfare activities, utilizing their expertise to help their communities and vulnerable groups. Since 2021, Johnson & Johnson employees in China have provided more than 30,000 hours of volunteer service and offered professional volunteer services to more than 10 social organizations.

Song Weiqun said: "Johnson & Johnson is committed to improving human health. The aspirations of 1.4 billion Chinese people for a better life and their demand for high-quality medical products and services are the fundamental driving force behind our long-term confidence in the Chinese market. On this new journey, Johnson & Johnson will continue to spare no effort in supporting the development of China's healthcare industry, practicing corporate social responsibility through concrete actions, continuously enhancing the accessibility and affordability of innovative medical solutions, supporting the improvement of grassroots disease prevention, treatment, and health management capabilities, and allowing more innovative and high-quality medical resources to benefit more patients and families, promoting the health and well-being of the people."